DD141261A5 - Prostaglandin-derivate - Google Patents

Prostaglandin-derivate Download PDF

Info

Publication number: DD141261A5
Authority: DD; German Democratic Republic
Prior art keywords: prostaglandin; group; steroid hormone; pgf; pgfe
Prior art date: 1978-01-31

Application number

DD79210712A

Other languages

German (de)

English (en)

Inventor

Satoru Enomoto

Kiro Asano

Humio Tamura

Hiromitsu Tanaka

Original Assignee

Kureha Chemical Ind Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-01-31

Filing date

1979-01-30

Publication date

1980-04-23

1979-01-30 Application filed by Kureha Chemical Ind Co Ltd filed Critical Kureha Chemical Ind Co Ltd

1980-04-23 Publication of DD141261A5 publication Critical patent/DD141261A5/de

Links

150000003180 prostaglandins Chemical class 0.000 title claims description 50
238000006243 chemical reaction Methods 0.000 claims description 33
150000001875 compounds Chemical class 0.000 claims description 28
239000003270 steroid hormone Substances 0.000 claims description 26
229960005309 estradiol Drugs 0.000 claims description 24
229930182833 estradiol Natural products 0.000 claims description 24
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 23
238000000034 method Methods 0.000 claims description 23
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 15
239000002904 solvent Substances 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 11
229940094443 oxytocics prostaglandins Drugs 0.000 claims description 9
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 8
230000021736 acetylation Effects 0.000 claims description 8
238000006640 acetylation reaction Methods 0.000 claims description 8
-1 propionyloxy group Chemical group 0.000 claims description 7
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 4
125000004043 oxo group Chemical group O=* 0.000 claims description 4
239000000186 progesterone Substances 0.000 claims description 4
229960003387 progesterone Drugs 0.000 claims description 4
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 2
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 2
229960001348 estriol Drugs 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 9
235000011054 acetic acid Nutrition 0.000 claims 3
150000004820 halides Chemical class 0.000 claims 3
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
150000008064 anhydrides Chemical class 0.000 claims 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 claims 1
239000005711 Benzoic acid Substances 0.000 claims 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims 1
229940061641 androsterone Drugs 0.000 claims 1
235000010233 benzoic acid Nutrition 0.000 claims 1
229960004544 cortisone Drugs 0.000 claims 1
235000019260 propionic acid Nutrition 0.000 claims 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
229960003604 testosterone Drugs 0.000 claims 1
239000000047 product Substances 0.000 description 35
238000002329 infrared spectrum Methods 0.000 description 26
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
238000000921 elemental analysis Methods 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
239000000243 solution Substances 0.000 description 23
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
241000699670 Mus sp. Species 0.000 description 20
230000035935 pregnancy Effects 0.000 description 20
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
230000000694 effects Effects 0.000 description 13
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 11
239000000203 mixture Substances 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 10
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
239000012266 salt solution Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
239000002253 acid Substances 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
208000001871 Tachycardia Diseases 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
238000010253 intravenous injection Methods 0.000 description 5
230000001766 physiological effect Effects 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
239000000523 sample Substances 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000006794 tachycardia Effects 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000012442 inert solvent Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000012046 mixed solvent Substances 0.000 description 4
ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 4
239000007858 starting material Substances 0.000 description 4
ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
229940079593 drug Drugs 0.000 description 3
102000015694 estrogen receptors Human genes 0.000 description 3
108010038795 estrogen receptors Proteins 0.000 description 3
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 2
ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 2
101710134784 Agnoprotein Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
239000012496 blank sample Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
230000000938 luteal effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
230000032696 parturition Effects 0.000 description 2
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
239000012264 purified product Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
POKRQUNDSGAZIA-IPDJLGJESA-N (2E)-7-[(1R,2S)-2-octylcyclopentyl]hepta-2,4-dienoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCC=C\C=C\C(O)=O POKRQUNDSGAZIA-IPDJLGJESA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000237519 Bivalvia Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
244000290594 Ficus sycomorus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
244000237786 Lathyrus tuberosus Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000019255 Menstrual disease Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
241000207836 Olea <angiosperm> Species 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
230000000397 acetylating effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000010828 elution Methods 0.000 description 1
150000002159 estradiols Chemical class 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
230000012173 estrus Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003145 progesterone derivatives Chemical class 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DD79210712A 1978-01-31 1979-01-30 Prostaglandin-derivate DD141261A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP53009652A JPS5850236B2 (ja)	1978-01-31	1978-01-31	プロスタグランジン類↓−ステロイドホルモン結合体

Publications (1)

Publication Number	Publication Date
DD141261A5 true DD141261A5 (de)	1980-04-23

Family

ID=11726136

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD79210712A DD141261A5 (de)	1978-01-31	1979-01-30	Prostaglandin-derivate

Country Status (11)

Country	Link
JP (1)	JPS5850236B2 (pl)
AT (1)	AT373268B (pl)
BE (1)	BE873380A (pl)
BG (1)	BG34611A3 (pl)
DD (1)	DD141261A5 (pl)
HU (1)	HU182517B (pl)
PL (1)	PL127780B1 (pl)
RO (1)	RO77375A (pl)
SU (1)	SU944502A3 (pl)
YU (1)	YU42174B (pl)
ZA (1)	ZA79305B (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1983004021A1 (en) *	1982-05-06	1983-11-24	Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt.	2,3,4-trinor-1,5-inter-m-phenylene-prostacycline-i2 analogues, process for the preparation thereof and pharmaceutical compositions containing the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2022013665A (es) *	2020-05-01	2022-11-30	Ripple Therapeutics Corp	Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.

1978
- 1978-01-30 SU SU782719054A patent/SU944502A3/ru active
- 1978-01-31 JP JP53009652A patent/JPS5850236B2/ja not_active Expired
1979
- 1979-01-05 AT AT0007979A patent/AT373268B/de not_active IP Right Cessation
- 1979-01-10 BE BE0/192818A patent/BE873380A/fr not_active IP Right Cessation
- 1979-01-24 ZA ZA79305A patent/ZA79305B/xx unknown
- 1979-01-29 HU HU79KU540A patent/HU182517B/hu not_active IP Right Cessation
- 1979-01-29 RO RO7996423A patent/RO77375A/ro unknown
- 1979-01-30 DD DD79210712A patent/DD141261A5/de not_active IP Right Cessation
- 1979-01-30 BG BG042307A patent/BG34611A3/xx unknown
- 1979-01-30 YU YU208/79A patent/YU42174B/xx unknown
- 1979-01-31 PL PL1979213122A patent/PL127780B1/pl unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1983004021A1 (en) *	1982-05-06	1983-11-24	Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt.	2,3,4-trinor-1,5-inter-m-phenylene-prostacycline-i2 analogues, process for the preparation thereof and pharmaceutical compositions containing the same
AT382372B (de) *	1982-05-06	1987-02-25	Chinoin Gyogyszer Es Vegyeszet	Verfahren zur herstellung neuer 2,3,4-trinor-1,5 -inter-m-phenylen-prostacyclin-i2-analoga und von deren salzen

Also Published As

Publication number	Publication date
SU944502A3 (ru)	1982-07-15
PL213122A1 (pl)	1979-10-08
YU20879A (en)	1983-01-21
PL127780B1 (en)	1983-11-30
ATA7979A (de)	1983-05-15
ZA79305B (en)	1980-01-30
JPS54103858A (en)	1979-08-15
YU42174B (en)	1988-06-30
BE873380A (fr)	1979-07-10
AT373268B (de)	1984-01-10
RO77375A (ro)	1981-11-04
JPS5850236B2 (ja)	1983-11-09
HU182517B (en)	1984-01-30
BG34611A3 (en)	1983-10-15

Legal Events

Date	Code	Title	Description
1995-12-21	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
EP0624594B1 (de)	1999-08-11	Monomere Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel
DE2900061C2 (de)	1982-04-01	Prostaglandin-Derivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung
EP1284273B1 (de)	2010-09-29	Estra-1,3,5(10)-trien-3-sulfamat Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE3873007T2 (de)	1992-12-03	Kathartica.
DE2645307C2 (pl)	1988-10-13
US4230702A (en)	1980-10-28	Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
DE2932607A1 (de)	1980-02-21	Chlorambucilderivate, verfahren zur herstellung derselben und antitumormittel mit einem gehalt derselben
CH637829A5 (de)	1983-08-31	Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor.
DE2758279A1 (de)	1978-06-29	7 xi-(alkoxycarbonyl)-6 xi-alkyl/halogen-17-hydroxy-3-oxo-17 alpha-pregn-4- en-21-carbonsaeure-gamma-lactone und entsprechende 21-carbonsaeuren, deren salze sowie ester und verfahren zu deren herstellung
DE1951790C3 (de)	1978-10-26	In 17-StelIung veresterte Steroid-21-phosphate der Pregnanreihe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Zubereitungen
DD141261A5 (de)	1980-04-23	Prostaglandin-derivate
DE1904325C3 (de)	1978-10-26	9alpha-unsubstituierte 1 lbeta-Chlor-19-norsteroide, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE2741771A1 (de)	1978-03-23	Neue 2,2-dimethyl-19-nor-steroide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE1793677C3 (de)	1978-10-26	Verfahren zur Herstellung von 8-Hydroxygona-13r5(10)-trienen und 8-Hydroxygona-13,5(10),9(ll)-tetraenen und gewisse neue 8-Hydroxygona-133(10)-triene und 8-Hydroxygona-13Ä10),9(l l)-tetraene
CH526527A (de)	1972-08-15	Verfahren zur Herstellung eines neuen 6a-Methyl-19-nor-progesterons
DE2336431C2 (de)	1982-09-23	1.3-oxygenierte 8 alpha-Östratriene, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
CH616691A5 (en)	1980-04-15	Process for the preparation of steroid compounds and their use.
EP0707593B1 (de)	1997-12-29	Oral estrogen wirksame ester des 14 alpha,15 alpha-methylen-estradiols
DE1593225C3 (de)	1976-02-26	Reine alpha- und beta-anomere, optisch aktive 3-(2'-Tetrahydropyranyloxy)-Derivate von Steroid-Östrogenen sowie Verfahren zu deren Herstellung
DE1930982C3 (de)	1975-02-27	6alpha-Fluor-2,9alpha,11 betatrichlor-16alpha-methyl-verbindungen der Pregnanreihe
DE2357778C3 (de)	1977-10-06	Neue Ester von 21-Mercaptosteroiden, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zubereitungen
AT341117B (de)	1978-01-25	Verfahren zur herstellung von neuen 11beta-chlorsteroiden der pregnanreihe
DE2006635C (de)	1973-06-28	löalpha, 17alpha (propen 2 yhden dioxy) 9 fluor 1 lbeta, 21 dihydroxy Delta hoch 1,4 pregnadiene bzw deren 21 Ester, Verfahren zu ihrer Herstellung und diese als alleinigen Wirkstoff ent haltende pharmazeutische Mittel
DE1228257B (de)	1966-11-10	Verfahren zur Herstellung von 8-Iso-17alpha-aethinyl-oestradiol sowie von 3-AEthern u3-Estern bzw. 3, 17-Diestern desselben
DE1668857C (de)	1972-04-20	6 alpha, 9 alpha Difluorprednisolon 17 valerat 21 acetat